{
    "clinical_study": {
        "@rank": "158023", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "SBI 2.5 g", 
                "arm_group_type": "Active Comparator", 
                "description": "Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g"
            }, 
            {
                "arm_group_label": "SBI 5.0g", 
                "arm_group_type": "Active Comparator", 
                "description": "Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy\n      serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g BID and SBI 5.0 g versus\n      placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy."
        }, 
        "brief_title": "Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-associated Enteropathy", 
        "condition_browse": {
            "mesh_term": [
                "Intestinal Diseases", 
                "HIV Enteropathy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is evaluating the effectiveness of the oral nutritional therapy serum-derived\n      bovine immunoglobulin protein isolate (SBI) 2.5g BID and SBI 5.0g compared to placebo for 6\n      months on gastrointestinal symptoms, nutritional status and quality of life in HIV+ subjects\n      with HIV-associated enteropathy. In addition, the effects of SBI on pro-inflammatory\n      intestinal microbial populations, bacterial translocation, intestinal barrier function, and\n      systemic immune activation will be investigated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of HIV-1 infection\n\n          -  Plasma HIV viral load \u226440 copies/mL\n\n          -  Maintained virologic suppression for 1 year\n\n          -  Stable ART regimen\n\n          -  History of HIV-associated diarrhea defined as abnormal passage of 3 or more unformed\n             stools per day or a liquid stool volume greater than 200 g per day for at least 4\n             weeks duration\n\n        Exclusion Criteria:\n\n          -  Positive stool test for pathogenic bacteria, C. difficile or ova and parasites\n\n          -  Conditions that require chronic therapy that is known to alter gut microbiota\n\n          -  Antibiotics within 2 weeks of screening (exception: prophylaxis antibiotics)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828593", 
            "org_study_id": "EH6001"
        }, 
        "intervention": {
            "arm_group_label": [
                "SBI 2.5 g", 
                "SBI 5.0g"
            ], 
            "description": "SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free.  SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.", 
            "intervention_name": "Serum-derived bovine immunoglobulin protein isolate (SBI)", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90015"
                    }, 
                    "name": "AIDS Research Alliance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "Univ of California Davis CARES Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Univ of California SF"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33308"
                    }, 
                    "name": "Therafirst"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33166"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "600654"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02461"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45206"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76107"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.", 
        "other_outcome": {
            "measure": "Effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation", 
            "safety_issue": "No", 
            "time_frame": "through 6 months"
        }, 
        "overall_official": {
            "affiliation": "University of California, Davis", 
            "last_name": "David M Asmuth, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency of daily unformed bowel movements", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828593"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentration of Vitamin D and E", 
                "safety_issue": "No", 
                "time_frame": "through 6 months"
            }, 
            {
                "measure": "Nutrient absorption", 
                "safety_issue": "No", 
                "time_frame": "through 6 months"
            }, 
            {
                "measure": "Body measurements: weight, mid-upper arm circumference (MUAC), waist:hip ratio, body mass index (BMI), total body water (TBW), fat-free mass (FFM), body cell mass (BCM)", 
                "safety_issue": "No", 
                "time_frame": "through 6 months"
            }, 
            {
                "measure": "Daily stool consistency", 
                "safety_issue": "No", 
                "time_frame": "through 6 months"
            }, 
            {
                "measure": "Gastrointestinal symptoms", 
                "safety_issue": "No", 
                "time_frame": "through 6 months"
            }
        ], 
        "source": "Entera Health, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Entera Health, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}